US3723032062 - GMAB - A1WZYB (XNAS)
GENMAB A/S - AMERICAN DEPOSITARY SHARES Hinterlegungsschein
26,48 USD
Aktuelle Kurse von GENMAB A/S - AMERICAN DEPOSITARY SHARES
Börse | Ticker | Währung | Letzter Umsatz | Kurs | Tagesveränderung | Tagesveränderung % |
---|---|---|---|---|---|---|
NASDAQ |
GMAB
|
USD
|
19.09.2024 22:00
|
26,48 USD
| 26,20 USD | 1,07 % |
Performance
Tag | Woche | Monat | 3 Monate | 6 Monate | 1 Jahr | 5 Jahre |
---|---|---|---|---|---|---|
0,00 % | -1,56 % | -4,06 % | 2,64 % | -10,66 % | -29,12 % | 30,64 % |
Firmenprofil zu GENMAB A/S - AMERICAN DEPOSITARY SHARES Hinterlegungsschein
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and DuoHexaBody-CD37 for treating hematological malignancies. The company's also develops products, which is in Phase 2 comprise Teclistamab for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. In addition, it has approximately 20 active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with CureVac AG for the research and development of differentiated mRNA-based antibody products; AbbVie for the development of epcoritamab; and collaborations with BioNTech, Janssen, Novo Nordisk A/S, BliNK Biomedical SAS, and Bolt Biotherapeutics, Inc. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.
Investierte Fonds
Folgende Fonds haben in GENMAB A/S - AMERICAN DEPOSITARY SHARES investiert:
Fonds | Vol. in Mio 77,21 | Anteil (%) 0,18 % |
Unternehmensdaten GENMAB A/S - AMERICAN DEPOSITARY SHARES Hinterlegungsschein
Name GENMAB A/S - AMERICAN DEPOSITARY SHARES
Firma Genmab A/S
Symbol GMAB
Website https://www.genmab.com
Heimatbörse
NASDAQ
WKN A1WZYB
ISIN US3723032062
Wertpapierart Hinterlegungsschein
Sektor Healthcare
Branche Biotechnology
CEO Dr. Jan G.J. van de Winkel Ph.D.
Marktkapitalisierung 17 Mrd.
Land Dänemark
Währung USD
Mitarbeiter 2,5 T
Adresse Kalvebod Brygge 43, 1560 Copenhagen
IPO Datum 2009-06-01
Aktien-Splits
Datum | Split |
---|---|
01.05.2018 | 5:1 |
Aktien Kennungs-Wechsel
Datum | Von | Zu |
---|---|---|
22.07.2019 | GMXAY | GMAB |
Ticker Symbole
Name | Symbol |
---|---|
Frankfurt | GE91.F |
NASDAQ | GMAB |
Weitere Aktien
Investoren die GENMAB A/S - AMERICAN DEPOSITARY SHARES halten haben auch folgende Aktien im Depot:
Die Finanzplattform goSPATZ trackt und analysiert Investitionen und Portfolios.
Vom Wertpapier-Depot bis zum Crypto-Kauf.
Nützlich, simpel und kostenlos. Aktien, ETF, ETC, ETN, Indizes, Fonds, Anleihen, Zertifikate, Währungen, Optionen, Bezugsrechte.
Nützlich, simpel und kostenlos. Aktien, ETF, ETC, ETN, Indizes, Fonds, Anleihen, Zertifikate, Währungen, Optionen, Bezugsrechte.
All rights reserved © LCP GmbH 2024